Colorectal Cancer Biomarkers
Key Points
Key Points
Current evidence-based recommendations for the molecular testing of CRC tissues to guide EGFR-targeted therapies and conventional chemotherapy regimens were developed through collaboration of four societies: American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and American Society of Clinical Oncology (ASCO).
Diagnosis
...Diagnosis...
...cinoma patients being considered for...
...0 (BRAF c. 1799 (p.V600) mutational...
...F p.V600 mutational analysis should b...
Clinicians should order mismatch repair status...
...icient evidence to recommend BRAF c.1799 p...
...e is insufficient evidence to recommend PIK3CA...
...fficient evidence to recommend PTEN analysis [exp...
...c or recurrent colorectal carcinoma tissues...
Formalin fixed paraffin embedded tissue is an...
...ratories must use validated colorectal c...
...of molecular biomarker testing for colore...
...ust validate the performance of IHC...
...ies must provide clinically appropriate tur...
...IHC biomarker testing in colorectal carcinom...
...uld establish policies to ensure efficient allo...
...e patient’s medical team, including pathologist...
...ries that require send out of tests for...
...sts must evaluate candidate specimens for biomark...
...s should use colorectal carcinoma molecular...
...arcinoma molecular biomarker results shou...
...al carcinoma molecular biomarker testing reports...
...boratories must incorporate colorectal carcinoma...
...utcomes of RAS Mutations and Anti-EGFR Therapy...
...ordance Rates Between Primary and...